Ask AI
ProCE Banner Activity

Multidisciplinary Care Integration in Myelofibrosis

Slideset

In these slides, the progressive course of myelofibrosis and key considerations for individualized management, including treatment goals, assessment of spleen volume and symptom burden, use and monitoring of JAK inhibitors, and the role of hematopoietic stem cell transplantation is reviewed. The module also addresses treatment-related toxicities, multidisciplinary care, and the importance of aligning therapy with disease characteristics, patient priorities, and evolving clinical needs, while highlighting clinical trial participation as an important avenue for expanding future treatment options.

Released: October 26, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education In partnership with Smart Patients, Inc.

ProCE Banner

Supporters

This educational activity is supported by independent medical education grants from GSK, Incyte Corporation, and Sobi.

GSK

Incyte Corporation

Sobi

Partners

Smart Patients, Inc.

ProCE Banner

Target Audience

This activity is intended for oncologists, hematologists, nurses, pharmacists, and other healthcare professionals who care for patients with myelofibrosis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate strategies for coordinated multidisciplinary care team and shared decision-making strategies to optimize patient-centered management of myelofibrosis, including symptom control and quality-of-life considerations

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.